NCT07382778已完成不适用
A Multi-center, Open-label, Observational Study to Compare and Evaluate the Efficacy and Safety of Livalozet® According to the Presence or Absence of Diabetes Mellitus in Hypercholesterolemia Patients
JW Pharmaceutical1 个研究点 分布在 1 个国家目标入组 1,538 人开始时间: 2022年10月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,538
- 试验地点
- 1
- 主要终点
- Percent change from baseline in LDL-C level at Week 24
研究概览
简要总结
A Multi-center, Open-label, Observational Study to Compare and Evaluate the Efficacy and Safety of Livalozet® according to the Presence or Absence of Diabetes Mellitus in Hypercholesterolemia Patients
详细描述
A Multi-center, Open-label, Observational Study
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged ≥19 years
- •Diagnosed with hypercholesterolemia
- •LDL-C level meets cardiovascular/cerebrovascular risk group classification
- •Willing to participate for 12 months
- •Provided written informed consent
排除标准
- •- Contraindications to Livalozet®
研究组 & 干预措施
Hypercholesterolemia with Diabetes Mellitus
Observational study; LDL-C and lipid parameters will be followed; no intervention assigned.
Hypercholesterolemia without Diabetes Mellitus
Observational study; LDL-C and lipid parameters will be followed; no intervention assigned.
结局指标
主要结局
Percent change from baseline in LDL-C level at Week 24
时间窗: From enrollment to the end of treatment at 24 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid TumorsNCT07321574Shanghai AB PharmaTech Ltd.110
尚未招募
不适用
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver TransplantationHepatocellular CarcinomaNCT07310836Ningbo Medical Center Lihuili Hospital300
尚未招募
1 期
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNCT07339527Sun Yat-sen University60
尚未招募
2 期
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerCervical CancerNCT07348861Zheng Min25
尚未招募
2 期
Glofitamab Combined With CAR-T Therapy in R/R DLBCLNCT07326371Ruijin Hospital24